Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials

Bowering, Gale
November 2012
Canadian Oncology Nursing Journal;Fall2012, Vol. 22 Issue 4, p287
Book Review
The article reviews the book ``Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials,'' by T.M. Beer and L.W. Axmaker.


Related Articles

  • Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials. Bowering, Gale // Canadian Oncology Nursing Journal;Fall2012, Vol. 22 Issue 4, p288 

    No abstract available.

  • Clinical Trial Information As a Measure of Quality Cancer Care. Wei Chua; Clarke, Stephen J. // Journal of Oncology Practice;May2010, Vol. 6 Issue 3, p170 

    In this article the authors discuss on using clinical trial information as quality measure in medical oncology. It states that participation of patients in clinical trials enables them to access new treatment options and improved patient outcomes. Moreover, it mentions measures that allows...

  • Will my child do better if she enrolls in a clinical trial? Smith, Malcolm A.; Joffe, Steven // Cancer (0008543X);Oct2018, Vol. 124 Issue 20, p3965 

    The question of whether children with cancer who enroll in clinical trials have superior outcomes compared with those who do not participate has been pursued for more than 4 decades, and recent studies have provided conflicting answers. Whether clinical trial participation influences outcome has...

  • Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem. Breccia, Massimo; Alimena, Giuliana // Cardiovascular & Haematological Disorders - Drug Targets;Mar2009, Vol. 9 Issue 1, p21 

    The majority of patients with chronic phase chronic myeloid leukaemia (CP-CML) treated with imatinib achieves cytogenetic disease remission. Molecular monitoring for residual disease has prognostic significance: rising BCR-ABL levels may provide earliest indication that a patient has become...

  • Sorafenib a worthy opponent for advanced renal cancer.  // PharmacoEconomics & Outcomes News;7/28/2007, Issue 533, p3 

    The article reports the results of a research on sorafenib as a treatment for advanced renal cancer. Canadian researchers claim that sorafenib is a cost-effective treatment for advanced renal cancer from a Canadian provincial Ministry of Health perspective. To examine the lifetime costs and...

  • Firm's Software Brings Together Resources for Patients' Recovery. Gallant, Julie // San Diego Business Journal;7/30/2012, Vol. 33 Issue 31, p4 

    The article features Naser Partovi, founder of Sanitas Inc. in La Jolla in San Diego, California after the death of his wife Ioana due to breast cancer. It says that Partovi has invented an application called Wellaho which can help patients with heart failure, diabetes, and other chronic...

  • Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews. Vale, Claire L.; Tierney, Jayne F.; Burdett, Sarah // BMJ: British Medical Journal;5/4/2013, Vol. 346 Issue 7906, p15 

    The article presents a study analyzing the quality of controlled trials conducted on cancer patients in systematic reviews. According to the study, trials are unreliable and thus reviews should be conducted cautiously. As mentioned, study was conducted on 95 published trials. It further mentions...

  • Exploratory research into cancer patients' attitudes to clinical trials. Ramers-Verhoeven, Corina W.; Perrone, Francesco; Oliver, Kathy // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    A qualitative survey was carried out in six countries to gather insights into potential barriers to patient participation in cancer clinical trials (CTs) to help stakeholders develop strategies to improve recruitment and participation. While the research was exploratory in nature, the findings...

  • New Clinical Trials Under Way.  // Journal of Oncology Navigation & Survivorship;Feb2015, Vol. 6 Issue 1, p42 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics